Perakizumab Overview

Introduction of Perakizumab

Perakizumab is a recombinant humanized (from mouse) IgGκ monoclonal antibody (mAb) binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). It was discovered and developed by Roche/Genentech) with the developmental name RG4934 (RO5310074), for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis. Phase-I clinical trials in psoriatic arthritis were started in USA and Australia in February 2011 but discontinued in July 2012.

Mechanism of Action of Perakizumab

Perakizumab works by targeting IL-17A and inhibiting its interaction with the IL-17 receptor. IL-17A can be produced by a range of different cell types as part of both the adaptive and innate immune responses, including neutrophils, macrophages, mast cells, Group 3 innate lymphoid cells, T helper 17 (Th17) cells and cytotoxic T cells. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. IL-17A plays a key role in the pathogenesis of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis and is up-regulated in lesional skin in contrast to non-lesional skin of plaque psoriasis patients and in synovial tissue of psoriatic arthritis patients. The frequency of IL-17-producing cells was also significantly higher in the subchondral bone marrow of facet joints from patients with ankylosing spondylitis. Perakizumab selectively binds to and neutralizes IL-17A, preventing its interaction with the IL-17 receptors expressed on keratinocytes, fibroblast-like synoviocytes, endothelial cells, chondrocytes and osteoblasts. As a result, perakizumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL-17A-mediated contributions to autoimmune and inflammatory diseases.

Fig.1 Mechanism of action of perakizumab

What We Provide

Therapeutic Antibody

Perakizumab

We provide high-quality Perakizumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

For research use only. Not intended for any clinical use.